Related references
Note: Only part of the references are listed.Nivolumab treatment of relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults
Pengpeng Liu et al.
BLOOD (2020)
Epstein-Barr virus NK and T cell lymphoproliferative disease: report of a 2018 international meeting
Jeffrey I. Cohena et al.
LEUKEMIA & LYMPHOMA (2020)
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Seok-Jin Kim et al.
CANCER RESEARCH AND TREATMENT (2019)
Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy
Jae-Ho Yoon et al.
HAEMATOLOGICA (2019)
Epstein-Barr Virus-Associated T and NK-Cell Lymphoproliferative Diseases
Wook Youn Kim et al.
FRONTIERS IN PEDIATRICS (2019)
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer A Systematic Review
Michael R. Cook et al.
JAMA ONCOLOGY (2019)
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
Paul La Rosee et al.
BLOOD (2019)
Immune checkpoint blockade in infectious diseases
Michelle N. Wykes et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Share Paper
